ARALU - Phase 2, Open-label, Randomized Study to Investigate Safety and Efficacy of Pluvicto Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer in Addition to Standard of Care Treatment with Nubeqa and ADT
Publication date: October 2026 Source: European Urology Focus, Volume 12, Issue 5 Author(s): Julia Franz, Joachim Brumberg, Michael Mix, Philipp T. Meyer, Ken Herrmann, Christian Gratzke, August Sigle
ARALU - Phase 2, Open-label, Randomized Study to Investigate Safety and Efficacy of Pluvicto Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer in Addition to Standard of Care Treatment with Nubeqa and ADT. // European Urology Focus. – URL: https://www.sciencedirect.com/science/article/pii/S2405456926001197?dgcid=rss_sd_all
ARALU - Phase 2, Open-label, Randomized Study to Investigate Safety and Efficacy of Pluvicto Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer in Addition to Standard of Care Treatment with Nubeqa and ADT. European Urology Focus. https://www.sciencedirect.com/science/article/pii/S2405456926001197?dgcid=rss_sd_all
“ARALU - Phase 2, Open-label, Randomized Study to Investigate Safety and Efficacy of Pluvicto Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer in Addition to Standard of Care Treatment with Nubeqa and ADT.” European Urology Focus.
@article{article93799,
title = {ARALU - Phase 2, Open-label, Randomized Study to Investigate Safety and Efficacy of Pluvicto Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer in Addition to Standard of Care Treatment with Nubeqa and ADT},
journal = {European Urology Focus},
url = {https://www.sciencedirect.com/science/article/pii/S2405456926001197?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...